Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005287-60
    Sponsor's Protocol Code Number:GBT2104-132
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-08-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-005287-60
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises
    Studio multicentrico, randomizzato, in doppio cieco, controllato con placebo su inclacumab a dose singola per ridurre la riammissione in partecipanti affetti da anemia falciforme e crisi vaso occlusive ricorrenti
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises
    Studio di una dose singola di inclacumab per ridurre la riammissione in partecipanti con anemia falciforme e crisi vaso-occlusive ricorrenti
    A.3.2Name or abbreviated title of the trial where available
    A trial to evaluate inclacumab for VOC prevention
    Studio per valutare inclacumab per la prevenzione delle VOC
    A.4.1Sponsor's protocol code numberGBT2104-132
    A.5.4Other Identifiers
    Name:US IND numberNumber:144073
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGLOBAL BLOOD THERAPEUTICS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlobal Blood Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlobal Blood Therapeutics, Inc.
    B.5.2Functional name of contact pointKalyan Obalampalli
    B.5.3 Address:
    B.5.3.1Street Address181 Oyster Point Blvd.
    B.5.3.2Town/ citySouth San Francisco
    B.5.3.3Post codeCA 94080
    B.5.3.4CountryUnited States
    B.5.4Telephone number0019162840777
    B.5.5Fax number000000
    B.5.6E-mailkobalampalli@gbt.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameInclacumab
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNInclacumab
    D.3.9.1CAS number 1256258-86-2
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive nameAnti P-selectin glycoprotein ligand-1 humanised monoclonal antibody
    D.3.9.4EV Substance CodeSUB205263
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Sickle Cell Disease
    Anemia falciforme
    E.1.1.1Medical condition in easily understood language
    Sickle Cell Disease and Recurrent Vaso occlusive Crises
    Anemia falciforme e crisi vaso-occlusive ricorrenti
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10040644
    E.1.2Term Sickle cell disease
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate the safety and efficacy of a single dose of inclacumab compared to placebo to reduce the incidence of re-admission to a healthcare facility for a vaso-occlusive crisis (VOC) after an admission for an index VOC in participants with sickle cell disease (SCD).
    L’obiettivo primario di questo studio è valutare la sicurezza e l’efficacia di una dose singola di inclacumab rispetto al placebo nel ridurre l’incidenza di riammissione presso una struttura sanitaria per una crisi vaso-occlusiva (CVO) dopo un ricovero per una CVO indice in partecipanti con anemia falciforme (AF).
    E.2.2Secondary objectives of the trial
    Additional objectives of the study are to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of inclacumab, the presence of antidrug antibodies (ADAs), and changes in quality of life (QOL).
    Gli ulteriori obiettivi dello studio consistono nel valutare la farmacocinetica (PK) e la farmacodinamica (PD) di inclacumab, la presenza di anticorpi anti-farmaco (Anti-Drug Antibody, [ADA]) e variazioni nella qualità della vita (QOL).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participant has an index VOC. The index VOC is any VOC that required admission to a healthcare facility and treatment with parenteral pain medication. An admission for the index VOC includes:
    a. A hospital admission, or
    b. An admission to an emergency room, observation unit, or infusion center for > and = 12 hours, or
    c. 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. for an acute episode of pain with no other cause other than a vaso-occlusive event that includes the following:
    • Uncomplicated VOC,
    • Acute chest syndrome (ACS),
    • Acute hepatic sequestration,
    • Acute splenic sequestration, or
    • Priapism.
    2. Participant has a confirmed diagnosis of SCD (any genotype).
    Documentation of SCD genotype is required and may be based on documented history of laboratory testing or confirmed by laboratory testing at Baseline.
    3. Participant is male or female, > and = 12 years of age at the time of informed consent.
    NOTE: Initial study enrollment will include only participants > and = 16 years of age until the DMC recommends to the Sponsor that adequate safety and PK data support the enrollment of participants 12 to 15 years of age. Sites will be informed by the Sponsor when participants 12 to 15 years of age may be enrolled.
    4. Participant is able to complete screening and receive study drug within 5 days following investigator-assessed resolution of index VOC (for example, hospital discharge, discontinuation of parenteral pain medication, or transition to oral pain medication).
    5. Participant has experienced between 2 and 10 VOCs (inclusive) within the 12 months prior to Screening as determined by documented medical history. The index VOC is not to be considered as one of the 2 to 10 events. A prior VOC is defined as an acute episode of pain that:
    • Has no medically determined cause other than a vaso-occlusive event, and
    • Results in a visit to a medical facility (hospital, emergency department, urgent care center, outpatient clinic, or infusion center) or results in a remote contact with a healthcare provider; and
    • Requires parenteral narcotic agents, parenteral nonsteroidal antiinflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics.
    6. Participants receiving erythropoiesis-stimulating agents (ESA, eg, erythropoietin [EPO]) must be on a stable dose for at least 90 days prior to Screening and expected to continue with the stabilized regimen throughout the course of the study.
    7. Participants receiving HU, L-glutamine, or voxelotor must be on a stable dose for at least 30 days prior to Screening and expected to continue with the stabilized regimen throughout the course of the study.
    8. Participant has adequate venous access, in the opinion of the Investigator, to comply with study procedures.
    9. Participant understands the study procedures and agrees to participate in the study by giving written informed consent or parental permission/written assent.
    10. Women of childbearing potential (WOCBP) are required to have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy tests on all subsequent clinic visits and must agree to use a highly effective method of contraception throughout the study period and for at least 165 days after dosing. (Section 6.2).
    Female participants will not be considered of childbearing potential if they are pre-menarchal, surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation, or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause, confirmed by follicle-stimulating hormone test results).
    1. Il partecipante presenta una VOC indice. Per VOC indice si intende qualsiasi VOC per cui è necessario il ricovero in una struttura sanitaria e trattamento con farmaci antidolorifici per via parenterale. Per ricovero per VOC indice si intende:
    a. un ricovero ospedaliero, o
    b. un’ammissione al PS/unità di osservazione o centro di infusione della durata > e =12H, o
    c. 2 visite al PS/unità di osservazione o centro di infusione per un periodo di 72H per un episodio acuto di dolore in assenza di altre cause diverse da un evento vaso-occlusivo che include:
    • VOC non complicata,
    • sindrome toracica acuta,
    • sequestro epatico acuto,
    • sequestro splenico acuto, o
    • priapismo.
    2. Il partecipante ha diagnosi confermata di AF (qualsiasi genotipo).
    La documentazione del genotipo AF è obbligatoria e può basarsi sull’anamnesi con test di laboratorio o confermata da test di laboratorio
    al basale.
    3. Il partecipante, uomo o donna, ha > e =12 anni alla firma del consenso informato.
    NOTA: l’arruolamento iniziale includerà solo partecipanti di età > e =16 anni fino a che il DMC non avrà raccomandato allo sponsor che dati di sicurezza e PK adeguati supportano l’arruolamento di partecipanti di età 12-15 anni. Lo sponsor avviserà i centri per arruolare partecipanti di età 12-15 anni.
    4. Il partecipante è in grado di completare lo screening e ricevere il farmaco dello studio entro 5gg dalla risoluzione della VOC indice valutata dallo sperimentatore (ad esempio dimissione dall’ospedale, interruzione del farmaco antidolorifico per via parenterale o passaggio al farmaco antidolorifico orale).
    5. In base all’anamnesi medica documentata, il partecipante ha manifestato da 2 a 10 VOC (estremi compresi) nei 12 mesi precedenti lo screening. La VOC indice non deve essere considerata come uno dei 2-10 episodi. Una VOC precedente è definita come un episodio acuto di dolore che:
    • non presenta una causa determinata dal punto di vista medico diversa da un evento vaso-occlusivo, e
    • richiede una visita presso una struttura medica (ospedale, PS, centro di assistenza d’emergenza, clinica ambulatoriale o centro di infusione) o un contatto remoto con un operatore sanitario; e
    • richiede l’uso di narcotici parenterali, farmaci antinfiammatori non steroidei (FANS) parenterali o un’intensificazione del trattamento con narcotici orali.
    6. I partecipanti in terapia con agenti stimolanti l’eritropoiesi (Erythropoiesis-Stimulating Agents, [ESA]; per es. eritropoietina [EPO]) devono aver assunto una dose stabile per almeno 90 giorni prima dello screening e devono continuare con il regime stabilizzato per tutto il corso dello studio.
    7. I partecipanti in terapia con idrossiurea (IU), L-glutammina o voxelotor devono aver assunto una dose stabile per almeno 30gg prima dello screening e dovranno continuare con il regime stabilizzato per tutto il corso dello studio.
    8. Il partecipante dispone di un accesso venoso adeguato che, a giudizio dello sperimentatore, gli consente di attenersi alle procedure dello studio.
    9. Il partecipante comprende le procedure dello studio e accetta di parteciparvi firmando il consenso informato scritto o il permesso genitoriale/l’assenso scritto.
    10. Le donne in età fertile devono risultare negative al test di gravidanza sul siero alla visita di screening e al test di gravidanza sulle urine in occasione di tutte le visite in clinica successive e devono acconsentire a utilizzare un metodo contraccettivo altamente efficace per tutta la durata dello studio e per almeno 165gg dopo la somministrazione (Sezione 6.2).
    Le partecipanti di sesso femminile non saranno considerate potenzialmente fertili se sono in pre-menarca, chirurgicamente sterili (sottoposte a isterectomia, salpingectomia bilaterale, legatura delle tube od ooforectomia bilaterale) o in post-menopausa (assenza di ciclo mestruale da 12 mesi senza una causa medica alternativa, confermata dai risultati del test dell’ormone follicolo-stimolante).
    E.4Principal exclusion criteria
    1. Participant is receiving regularly scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventative transfusion).
    2. Participant is taking or has received crizanlizumab (ADAKVEO®) within 90 days prior to Screening.
    3. Participant weighs > 133 kg (292 lbs.).
    4. Participant has a significant active and poorly controlled (unstable) hepatic disorder clearly unrelated to SCD.
    5. Participant has any of the following laboratory values at Screening:
    a. Absolute neutrophil count (ANC) < 1.0 × 109/L
    b. Platelet count < 80 × 109/L
    c. Hemoglobin < 4.0 g/dL for adults and < 5.0 g/dL for participants ages 12 to < 18 years of age
    d. Estimated glomerular filtration rate (eGFR) < 30 mL/min using Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula in adults, and Schwartz formula in adolescents.
    NOTE: Laboratory assessments conducted during Screening may be done by the local laboratory and must include at least a CBC with total and
    differential leukocyte count, platelet count, and hemoglobin, a chemistry panel with creatinine, and a serum pregnancy test to assess participant
    eligibility. Laboratory assessments conducted during the index VOC admission that are obtained within 7 days prior to screening may be used for Screening assessments if done as part of standard medical care.
    6. Participant has known active (symptomatic) COVID infection or tests positive for COVID-19 at any time during their index admission.
    7. Participant has a history of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to Screening including severe or unstable pulmonary hypertension.
    8. Participant has had treatment for a malignancy within the 12 months prior to Screening (except non-melanoma skin cancer and in situ cervical
    cancers).
    9. Participant has had a stroke within the 2 years prior to the Screening Visit.
    10. Participant has a positive test indicative of active malaria infection at Screening. Testing to be conducted at local laboratories in malariaendemic regions at the discretion of the Investigator.
    11. Participant has any confirmed clinically significant drug allergy and/or known hypersensitivity to monoclonal antibody therapeutics or
    formulation components of the study drug or a related drug.
    12. Participant has been treated with another investigational agent within 30 days or 5 half-lives of the investigational agent (whichever is
    greater) prior to Screening.
    13. Participant has had a major surgery within 8 weeks prior to the Screening Visit.
    14. Participant is pregnant, breastfeeding, or planning to become pregnant during the 90-day treatment period.
    15. Participant, parent, or legal guardian are unlikely to comply with the study procedures.
    16. Participant has other medical, or psychological, or behavioral conditions that, in the opinion of the Investigator, would: confound or interfere with evaluation of safety, efficacy, and/or PK of the investigational drug; prevent compliance with the study protocol; preclude informed consent; or render the participant, parent, or caretaker unable/unlikely to comply with the study procedures.
    1. Il partecipante sta ricevendo una terapia trasfusionale di GR regolarmente programmata (detta anche trasfusione cronica, profilattica o preventiva).
    2. Il partecipante assume o ha assunto crizanlizumab (ADAKVEO®) nei 90 giorni precedenti lo screening.
    3. Il partecipante pesa >133 kg (292 libbre).
    4. Il partecipante presenta un disturbo epatico attivo significativo e scarsamente controllato (instabile) chiaramente non correlato all’AF.
    5. Allo screening il partecipante presenta uno qualsiasi dei seguenti valori di laboratorio:
    a. conta assoluta dei neutrofili (Absolute Neutrophil Count, [ANC]) <1,0 × 109/l;
    b. conta piastrinica <80 × 10¿/l
    c. emoglobina <4,0 g/dl per gli adulti e <5,0 g/dl per i partecipanti
    di età compresa tra 12 e <18 anni; d. velocità di filtrazione glomerulare stimata (estimated Glomerular Filtration Rate, [eGFR]) <30 ml/min secondo la formula della Collaborazione sull’epidemiologia della malattia renale cronica (Chronic Kidney Disease-Epidemiology Collaboration, [CKD-EPI]) negli adulti e la formula di Schwartz negli adolescenti.
    NOTA: le valutazioni di laboratorio condotte durante lo screening possono essere eseguite dal laboratorio locale e devono includere almeno un emocromo completo con conta leucocitaria totale e differenziale, conta piastrinica ed emoglobina, un pannello ematochimico con creatinina e un test di gravidanza sul siero per valutare l’idoneità del partecipante. Le valutazioni di laboratorio eseguite durante il ricovero per la CVO indice nei 7 giorni precedenti lo screening possono essere utilizzate per le valutazioni di screening se eseguite nell’ambito della terapia standard.
    6. Il partecipante presenta un’infezione da COVID attiva (sintomatica) nota o
    risulta positivo per la COVID-19 in qualsiasi momento durante il ricovero indice.
    7. Il partecipante presenta un’anamnesi di malattia cardiaca o polmonare
    instabile o in peggioramento nei 6 mesi precedenti lo screening, inclusa
    ipertensione polmonare grave o instabile.
    8. Il partecipante è stato sottoposto a trattamento per un tumore maligno nei 12 mesi precedenti lo screening (fatta eccezione per tumore della pelle non melanomatoso e tumori della cervice in situ).
    9. Il partecipante ha avuto un ictus nei 2 anni precedenti la visita di
    screening.
    10. Il partecipante presenta un test positivo indicativo di infezione da malaria in fase attiva allo screening. Il test deve essere effettuato presso laboratori locali nelle regioni endemiche per la malaria a discrezione dello sperimentatore.
    11. Il partecipante presenta una qualsiasi allergia farmacologica clinicamente significativa confermata e/o ipersensibilità nota ad agenti terapeutici a base di anticorpi monoclonali o ai componenti della formulazione del farmaco dello studio o di un farmaco correlato.
    12. Il partecipante è stato trattato con un altro agente sperimentale nei 30 giorni o nelle 5 emivite dell’agente sperimentale (a seconda di quale sia di maggiore durata) precedenti lo screening.
    13. Il partecipante è stato sottoposto a un intervento di chirurgia maggiore nelle 8 settimane precedenti la visita di screening.
    14. Il partecipante è di sesso femminile ed è in gravidanza, sta allattando al seno o ha in programma una gravidanza durante il periodo di trattamento di 90 giorni.
    15. Il partecipante, genitore o tutore legale è poco propenso ad attenersi alle
    procedure dello studio.
    16. Il partecipante presenta altre condizioni mediche, psicologiche o comportamentali che, a giudizio dello sperimentatore, potrebbero: confondere o interferire con la valutazione della sicurezza, dell’efficacia e/o della PK del farmaco sperimentale; impedire la conformità al protocollo dello studio; precludere il consenso informato o rendere il partecipante, il genitore o l’assistente non in grado di/poco propenso ad attenersi alle procedure dello studio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint for this study is, following an index VOC, the proportion of participants with at least 1 VOC that required admission to
    a healthcare facility and treatment with parenteral pain medication within 90 days of randomization.
    An admission for a VOC includes:
    • A hospital admission, or
    • An admission to an emergency room, observation unit, or infusion center for > and = 12 hours, or
    • 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period.
    for an acute episode of pain with no other cause other than a vasoocclusive event that includes the following:
    • Uncomplicated VOC, or
    • Acute chest syndrome, or
    • Acute hepatic sequestration, or
    • Acute splenic sequestration, or
    • Priapism
    The definition of the index VOC requiring admission is the same as the primary endpoint VOC requiring admission.
    To ensure consistency across all sites, on-study VOCs to be used for the primary endpoint will be confirmed by adjudication by an independent,
    blinded panel comprised of experts in SCD. The primary efficacy analysis will be performed on adjudicated data.
    L’endpoint primario di questo studio è, a seguito di una CVO indice, la percentuale di partecipanti con almeno 1 CVO che abbia richiesto il ricovero in una struttura sanitaria e il trattamento con farmaci analgesici per via parenterale entro 90 giorni dalla randomizzazione.
    Per ricovero per CVO si intende:
    • un ricovero ospedaliero, oppure
    • un’ammissione al pronto soccorso, presso un’unità di osservazione o un centro di infusione della durata > e =12 ore, oppure
    • 2 visite al pronto soccorso, in un’unità di osservazione o un centro di infusione nell’arco di un periodo di 72 ore.
    per un episodio acuto di dolore in assenza di altre cause diverse da
    un evento vaso-occlusivo che include quanto segue:
    • CVO non complicata, o
    • sindrome toracica acuta, o
    • sequestro epatico acuto, o
    • sequestro splenico acuto, o
    • priapismo.
    La definizione di CVO indice che richiede il ricovero è la stessa di CVO dell’endpoint primario che richiede il ricovero.
    Al fine di garantire uniformità tra i centri dello studio, tutte le CVO riscontrate durante lo studio da utilizzare per l’endpoint primario saranno confermate mediante validazione da parte di un gruppo indipendente in cieco composto da esperti di AF. L’analisi primaria di efficacia sarà eseguita sui dati convalidati.
    E.5.1.1Timepoint(s) of evaluation of this end point
    within 90 days of randomization
    entro 90 giorni dalla randomizzazione
    E.5.2Secondary end point(s)
    The secondary efficacy endpoints of the study are the following:
    • Time to first VOC that required admission to a healthcare facility and treatment with parenteral pain medication within 90 days of
    randomization.
    • Proportion of participants with at least 1 VOC that required admission to a healthcare facility and treatment with parenteral pain medication within 30 days of randomization.
    • Rate of VOCs leading to a healthcare visit (hospital, emergency room, clinic visit, or remote contact with a healthcare provider) that requires parenteral pain medication (eg, parenteral narcotic agents or parenteral nonsteroidal anti-inflammatory drugs [NSAIDs]), or an increase in treatment with oral narcotics within 90 days following randomization.
    Gli endpoint di efficacia secondari dello studio sono i seguenti:
    • Tempo alla prima CVO con necessità di ricovero in una struttura sanitaria e
    trattamento con farmaci antidolorifici per via parenterale entro 90 giorni dalla randomizzazione.
    • Percentuale di partecipanti con almeno 1 CVO con necessità di ricovero
    in una struttura sanitaria e trattamento con farmaci antidolorifici per via parenterale entro 30 giorni dalla randomizzazione.
    • Tasso di CVO che necessitano di visita medica (ospedale, pronto soccorso, visita in clinica o contatto da remoto con un operatore sanitario) con somministrazione di un farmaco antidolorifico per via parenterale (ad es. narcotici parenterali o farmaci antinfiammatori non steroidei [FANS]) o intensificazione del trattamento con narcotici orali entro 90 giorni dalla randomizzazione.
    E.5.2.1Timepoint(s) of evaluation of this end point
    within 90 days of randomization
    entro 90 giorni dalla randomizzazione
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA6
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Colombia
    Dominican Republic
    Egypt
    Ghana
    Kenya
    Lebanon
    Nigeria
    Oman
    Saudi Arabia
    Tanzania, United Republic of
    Turkey
    United States
    Zambia
    France
    Germany
    Italy
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 20
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 255
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    adolescent participants (> and = 12 years of age)
    adolescenti > e = 12 anni di età
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 37
    F.4.2.2In the whole clinical trial 280
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants not enrolling in the OLE study will complete the study at the time of the last scheduled study procedures at the Day 161 visit. For participants who enroll in the OLE study, the Day 91 visit will be the final study visit. Participants may receive their first dose in the OLE study on the same day as the completion of the study assessments for the Day 91 visit.
    I partecipanti che non si arruolano nello studio di estensione in aperto (Open Label Extension, [OLE]) completeranno lo studio al momento delle ultime procedure dello studio programmate alla visita del Giorno 161.
    Per i partecipanti che si arruolano nello studio OLE, la visita del Giorno 91 sarà la visita finale dello studio. I partecipanti possono ricevere la loro prima dose nello studio OLE lo stesso giorno in cui sono state completate le valutazioni dello studio per la visita del Giorno 91.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-08-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-09-01
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-02-15
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 19:38:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA